» Articles » PMID: 24295550

Racial and Ethnic Differences in Statin Prescription and Clinical Outcomes Among Hospitalized Patients with Coronary Heart Disease

Overview
Journal Am J Cardiol
Date 2013 Dec 4
PMID 24295550
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

We aimed to evaluate the association among race and ethnicity, statin prescription, and clinical outcomes among hospitalized patients with coronary heart disease (CHD), adjusted for confounders. Racial and ethnic disparities in CHD outcomes may be related to differential uptake of preventive medications, but data from real-world settings are limited. This was a 1-year prospective study of patients with preexisting CHD without a documented contraindication to statin (n = 3,067, 35% black or Hispanic, 65% white or Asian, 35% women) who participated in an National Heart, Lung and Blood Institute clinical outcome study of patients admitted to a cardiovascular service. Baseline clinical and medication data and 30-day and 1-year outcomes (death or rehospitalization) were documented by electronic medical record, National Death Index, and/or standardized mail survey. Logistic regression was used to evaluate associations among race and ethnicity, statin prescription, and outcomes adjusted for demographics and co-morbidities. Black and Hispanic patients were more likely to be dead or rehospitalized at 1 year (odds ratio [OR] 1.23, 95% confidence interval [CI] 1.06 to 1.43) and less likely to report statin use before admission (62% vs 72%, adjusted OR 0.64, 95% CI 0.54 to 0.76) than whites and Asians; statin prescription was similar at discharge among blacks and Hispanics (81%) versus whites and Asians (84%). Black and Hispanic patients were more likely to have hypertension, diabetes, or renal failure and less likely to have health insurance than whites and Asians (p <0.05). The increased 1-year odds of death or rehospitalization in minorities versus whites and Asians were explained by demographics and co-morbidities not by differential statin prescription (adjusted OR 1.10, 95% CI 0.93 to 1.30). In conclusion, in this study of hospitalized patients with preexisting CHD, differential statin prescription did not explain racial and ethnic disparities in 1-year outcomes. Efforts to reduce CHD rehospitalizations should consider the greater burden of co-morbidities among racial and ethnic minorities.

Citing Articles

Financial resources, access to care, and quality of care mediate racial disparities in statin usage for secondary prevention.

Wong C, Marrast L, Rasul R, Srivastava R, Kuvin J, Roswell R PLoS One. 2024; 19(10):e0311724.

PMID: 39378232 PMC: 11460713. DOI: 10.1371/journal.pone.0311724.


Racial Disparities in Lipid Screening Among Patients With Coronary Artery Disease Narrowed in Primary Care Settings Supportive of Nurse Practitioners.

Brom H, Poghosyan L, Nikpour J, Todd B, Sliwinski K, Franz T J Nurs Regul. 2024; 14(3):20-32.

PMID: 39206146 PMC: 11349328. DOI: 10.1016/s2155-8256(23)00110-2.


Racial Differences in Fatal Out-of-Hospital Coronary Heart Disease and the Role of Income in the Atherosclerosis Risk in Communities Cohort Study (1987 to 2017).

Islek D, Alonso A, Rosamond W, Guild C, Butler K, Ali M Am J Cardiol. 2023; 194:102-110.

PMID: 36914508 PMC: 10079596. DOI: 10.1016/j.amjcard.2023.01.042.


Racial, Ethnic, and Socioeconomic Inequities in Glucagon-Like Peptide-1 Receptor Agonist Use Among Patients With Diabetes in the US.

Eberly L, Yang L, Essien U, Eneanya N, Julien H, Luo J JAMA Health Forum. 2022; 2(12):e214182.

PMID: 35977298 PMC: 8796881. DOI: 10.1001/jamahealthforum.2021.4182.


Factors Associated With PCSK9 Inhibitor Initiation Among US Veterans.

Derington C, Colantonio L, Herrick J, Cook J, King J, Rosenson R J Am Heart Assoc. 2021; 10(8):e019254.

PMID: 33821686 PMC: 8174184. DOI: 10.1161/JAHA.120.019254.


References
1.
Lewey J, Shrank W, Bowry A, Kilabuk E, Brennan T, Choudhry N . Gender and racial disparities in adherence to statin therapy: a meta-analysis. Am Heart J. 2013; 165(5):665-78, 678.e1. DOI: 10.1016/j.ahj.2013.02.011. View

2.
Smith Jr S, Benjamin E, Bonow R, Braun L, Creager M, Franklin B . AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation endorsed by.... J Am Coll Cardiol. 2011; 58(23):2432-46. DOI: 10.1016/j.jacc.2011.10.824. View

3.
Konety S, Vaughan Sarrazin M, Rosenthal G . Patient and hospital differences underlying racial variation in outcomes after coronary artery bypass graft surgery. Circulation. 2005; 111(10):1210-6. DOI: 10.1161/01.CIR.0000157728.49918.9F. View

4.
Baigent C, Keech A, Kearney P, Blackwell L, Buck G, Pollicino C . Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005; 366(9493):1267-78. DOI: 10.1016/S0140-6736(05)67394-1. View

5.
Maynard C, Wright S, Every N, Ritchie J . Racial differences in outcomes of veterans undergoing percutaneous coronary interventions. Am Heart J. 2001; 142(2):309-13. DOI: 10.1067/mhj.2001.116956. View